Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 18, 2025, Ginkgo Bioworks Holdings, Inc. (the "Company") announced that Dr. Reshma Shetty, the Company's President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly, the Company's Chief Executive Officer, on January 1, 2026. In connection with this transition, Dr. Shetty, who has served as the Company's Chief Operating Officer since its founding, will remain employed at the Company and will continue in a substantial policymaking function in her role of President and her service on the Board of Directors. Her new focus will be overseeing the Company's efforts to expand and use its autonomous lab to deliver its cell engineering service offerings. Dr. Kelly will assume the oversight and substantial policymaking functions of the principal operating officer.
Item 8.01. Other Events.
Jennifer Wipf, who was previously Chief Commercial Officer and General Manager, Discovery Solutions and Manufacturing, will assume responsibilities related to the Company's operations, including day-to-day commercial operations, procurement, deployment, facilities and real estate, and people operations, reporting to Dr. Kelly. Ms. Wipf previously led the Company's commercial function, where she played a key role in growing the company's cell engineering business. Before joining the Company, Ms. Wipf spent more than a decade at Merck & Co., gaining extensive experience in vaccine development, domestic and international plant management, and U.S. market commercial operations. Ms. Wipf holds an M.S. in Chemical Engineering from Stanford University and a B.S. in Bioengineering from the University of Arizona.